Evidence map›Paper›PMID 39237709›Full record

ReviewNature biomedical engineering2024

Engineering signalling pathways in mammalian cells.

Anna V Leopold, Vladislav V Verkhusha

Abstract readReview
In one paragraph

Review in Nature biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Anna V LeopoldMedicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Vladislav V VerkhushaMedicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland. vladislav.verkhusha@einsteinmed.edu.ORCID http://orcid.org/0000-0002-2083-8121

Funding

Near-Infrared Fluorescent Proteins, Biosensors and Optogenetic ToolsR35GM122567 · NIGMS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Vladislav Verkhusha · 2017 to 2026
$4.3M
Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) GM122567NIGMS NIH HHS R35 GM122567
6 · The paper itself

Abstract

In mammalian cells, signalling pathways orchestrate cellular growth, differentiation and survival, as well as many other processes that are essential for the proper functioning of cells. Here we describe cutting-edge genetic-engineering technologies for the rewiring of signalling networks in mammalian cells. Specifically, we describe the recombination of native pathway components, cross-kingdom pathway transplantation, and the development of de novo signalling within cells and organelles. We also discuss how, by designing signalling pathways, mammalian cells can acquire new properties, such as the capacity for photosynthesis, the ability to detect cancer and senescent cell markers or to synthesize hormones or metabolites in response to chemical or physical stimuli. We also review the applications of mammalian cells in biocomputing. Technologies for engineering signalling pathways in mammalian cells are advancing basic cellular biology, biomedical research and drug discovery.

Indexed as

Genetic EngineeringSignal TransductionAnimalsHumansMammals

Identifiers

PMID39237709
PMCPMC11852397

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.